Trial Profile

Immune Modulation by Abemaciclib in HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized Phase II Window Trial.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Nivolumab
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms AIM

Most Recent Events

05 Sep 2025 Status changed from recruiting to discontinued, because the standard of care had been updated in June to include neoadjuvant + adjuvant immunotherapy for Stage III-IVA HNSCC.
01 Aug 2025 Planned End Date changed from 30 Jun 2025 to 30 Aug 2025.
01 Aug 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Aug 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com